COVID-19 Enfeksiyonu ve Kardiyovasküler Hastalıklar

COVID-19 enfeksiyona ait bulgular genelde solunum sistemi ile ilişkili olmakla birlikte, hastaların bir kısmında başvuru anında kalp ve damar hastalık bulguları görülmektedir. Ölüm oranının bilinen kalp ve damar hastalıkları olan yaşlılarda en yüksek düzeyde olması nedeniyle COVID-19 pandemisinde kardiyoloji uzmanlarının hastalıkla mücadelede aktif görev almaları zorunlu hâle gelmiştir. Derlememizin amacı, COVID-19’lu hastalarda kalp yetmezliği, akut koroner sendrom, koagülopati ve hipertansiyon tanı ve tedavilerinin yönetimi ile birlikte sahada çalışan tüm tıp doktorlarına karşılaştıkları sorunlar ve sorular hakkında pratik öneriler sunmaktır.

COVID-19 Infection and Cardiovascular Diseases

Although the findings of COVID-19 infection are generally related with the respiratory system, symptoms of cardiovascular disease are observed in some patients at admission. As the highest mortality rate is seen in the elderly with known cardiovascular diseases, cardiologists have to take active parts in dealing with the disease during the COVID-19 pandemic. The purpose of this review is to provide practical advice on the issues and questions that all physicians working in the field can encounter, along with the management and diagnosis of heart failure, acute coronary syndrome, coagulopathy, and hypertension in patients with COVID-19.

Kaynakça

1. Wang D, Hu B, Hu C, et al. Clinical Characteris- tics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. [Epub ahead of print]. [CrossRef]

2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. [CrossRef]

3. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Feb 28. [Epub ahead of print]. [CrossRef]

4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the NewYork City Area. JAMA. 2020. [CrossRef]

5. Palmieri L, Andrianou X, Bella A, et al. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020. COVID-19 Surveillance Group. Available at: https://www.epicentro.iss.it/coronavirus/ bollettino/Report-COVID-2019_20_marzo_eng.pdf. Accessed Mar 23, 2020.

6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020:S0140- 6736;30566-3.

7. American College of Cardiology. Troponin and BNP Use in COVID-19. Available at: https://www.acc.org/latest-incardiology/articles/2020/03/18/15/25/troponin-and-bnp use-in covid19?utm_source=accupdate&utm_ medium=email_newsletter&utm_ content=20200320&utm_ campaign=accupdate. Accessed Mar 23, 2020.

8. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J. 2010;51:151-63. [CrossRef]

9. Bajwa EK, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med. 2008;36:2322-7. [CrossRef]

10. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diag- nosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636-48. [CrossRef]

11. Wang D, Li S, Jiang J, et al. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci.2019;62:187- 202. [CrossRef]

12. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19. [Epub ahead of print]. [CrossRef]

13. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-3. [CrossRef]

14. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension. 2014;64:1368-75. [CrossRef]

15. Laurent S, H Lip GY, McManus R, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. [cited 2020 Mar 24]; Available from: https://academic.oup. com/eurheartj/article-abstract/39/33/3021/5079119.

16. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. ReninAngiotensin-Aldosterone System Blockers and the Risk of Covid-19. NEJM. 01/05/2020. [CrossRef]

17. Welt FGP, Shah PB, HD Aronow, et al. from the American College of Cardiology’s (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI) Journal of the American College of Cardiology. March 2020. [CrossRef]

18. Romaguera R, Cruz-Gonzales I, Ojeda S, et al. Consensus document of the Interventional Cardiology and Heart Rhythm Associations of the Spanish Society of Cardiology on the management of invasive cardiac proce- dure rooms during the COVID-19 coronavirus outbreak. Revista Espanola de Cardiologia. Mar 3, 2020. [Epub ahead of print]. [CrossRef]

19. Karmpaliotis D, Kirtane AJ, Ruisi CP, et al. Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest. 2007;131:964-71. [CrossRef]

20. Coronavirus Disease 2019 (COVID-19) Provides Potent Reminder of the Risk of Infectious Agents. Available at: https://www.acc. org/latest-in-cardiology/ articles/2020/03/01/08/42/feature-coronavirus-disease2019-covid-19-provides-potent-reminder-of-the-risk-ofinfectious-agents. Acessed Mar 24, 2020.

21. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARSCoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Mar 4. [Epub ahead of print]. [CrossRef]

22. Khobragade SB, Gupta P, Gurav P, Chaudhari G, Gatne MM, Shingatgeri VM. Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models. J Pharmacol Pharmacother. 2013;4:116-24. [CrossRef]

23. Arunachalam K, Lakshmanan S, Maan A, Kumar N, Dominic P. Impact of Drug Induced Long QT Syndrome: A Systematic Review. J Clin Med Res. 2018;10(5):384-90. [CrossRef]

24. h t t p s : / / w w w . a c c . o r g / l a t e s t - i n - c a r d i o l o g y / articles/2020/03/27/14/00/ventricular-arrhythmia-risk-dueto-hydroxychloroquine-azithromycin-treatment-for-covid-19

25. Sağlık Bakanlığı COVID-19 (SARS-CoV-2 ENFEKSİYONU) REHBERİ (14.04.2020) Bilim Kurulu Çalışması.

Kaynak Göster